- Mar 12, 2026
- Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities
- Feb 12, 2026
- FUJIFILM Biotechnologies Unveils Biomanufacturing and Process Development Expansion in the United Kingdom
- Dec 23, 2025
- Fujifilm Celebrates the Completion of One of the Japan’s Largest Bio CDMO Facilities in Toyama Prefecture
- Sep 25, 2025
- FUJIFILM Biotechnologies Celebrates the Grand Opening of its Commercial-Scale Cell Culture Manufacturing Site in North Carolina
- Sep 19, 2025
- FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
- Jun 2, 2025
- Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions
- Apr 22, 2025
- FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-year U.S. Manufacturing Agreement Valued at Over $3 Billion
- Nov 5, 2024
- FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion
- May 15, 2024
- FUJIFILM Wako Pure Chemical Corporation Installs New Equipment to Triple Production Capacity of GMP-Compliant Raw Materials for Pharmaceutical Manufacturing (FUJIFILM Wako Pure Chemical)
- Apr 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Feb 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Dec 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Nov 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Jun 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mar 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
Germany